Blue background

Pipeline and Clinical Trials

Endocrine & Metabolic

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Relacorilant
Target Indication
Endogenous Cushing syndrome
Currently in Phase Three
Target Indication
Hypercortisolism associated with cortisol-secreting adrenal adenoma or hyperplasia
Currently in Phase Three
Target Indication
Extension study to evaluate long term safety
Phase Two
Compound
Miricorilant
Target Indication
NASH
Phase Two
Compound
Miricorilant
Target Indication
Antipsychotic-induced weight gain
Phase Two
Compound
Miricorilant
Target Indication
Antipsychotic-induced weight gain
Phase Two

Oncology

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Relacorilant + Nab-paclitaxel
Target Indication
Pancreatic cancer
Currently in Phase Three
Target Indication
Ovarian cancer
Phase Two Completed
Compound
Exicorilant + Enzalutamide
Target Indication
Castration-resistant prostate cancer
Phase Two
Compound
Mifepristone + Enzalutamide 1
Target Indication
Castration-resistant prostate cancer
Phase Two
Compound
Mifepristone + Nab-paclitaxel2
Target Indication
Metastatic GR-positive triple-negative breast cancer
Phase Two
Compound
Mifepristone + Pembrolizumab2
Target Indication
Metastatic HER2-negative breast cancer
Phase Two
Compound
Relacorilant + Enzalutamide2
Target Indication
Castration-resistant prostate cancer
Phase Two
Compound
Relacorilant + Pembrolizumab
Target Indication
Adrenocortical cancer with glucocorticoid excess
Phase One

Neurology

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
CORT113176
Target Indication
Amyotrophic lateral sclerosis (ALS)
Phase One

Addiction

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Mifepristone + Behavioral Therapy3
Target Indication
Alcohol use disorder
Phase Two Completed

Ophthalmology

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Mifepristone4
Target Indication
Central serous chorioretinopathy
Phase Two Completed

Psychiatry

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
CORT1082975
Target Indication
Post-traumatic stress disorder (PTSD)
Phase Two

Additional Areas of Research

Alzheimer’s disease
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Nonsmall cell lung cancer
Obesity

GR, glucocorticoid receptor; HER2, human epidermal growth factor receptor 2; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; NASH, nonalcoholic steatohepatitis.

Investigator Sponsored Trials

1University of Chicago and the National Cancer Institute.
2University of Chicago.
3Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism.

4Bay Area Retina Associates.
5VA Office of Research and Development (estimated study start date January 1, 2021).

Corcept's Clinical Trials

View Information on Clinical Trials

Clinical Trials